Format

Send to

Choose Destination
Ann Endocrinol (Paris). 2015 Feb;76(1 Suppl 1):1S47-52. doi: 10.1016/S0003-4266(16)30014-2.

Risk-benefit ratio for TSH- suppressive Levothyroxine therapy in differentiated thyroid cancer.

Author information

1
Service d'endocrinologie et des maladies métaboliques - Clinique endocrinologique Marc-Linquette, CHRU - 59037 Lille Cedex, France. Electronic address: christine.docao@chru-lille.fr.
2
Service d'endocrinologie et des maladies métaboliques - Clinique endocrinologique Marc-Linquette, CHRU - 59037 Lille Cedex, France.

Abstract

In the setting of differentiated thyroid cancer (DTC) management, < 0.1 mU/L TSH suppression has been proven to be beneficial for patients likely to have microscopic or macroscopic disease, as TSH has a direct trophic effect on thyroid cancer cells. However, the optimal degree of TSH reduction remains unclear for other categories of DTC patients with better prognosis. Excessive thyroid hormone replacement can lead to atrial fibrillation and osteoporosis. Therefore, levothyroxine dose should be carefully adjusted with respect to underlying individual health status, dynamically reassessed risk of relapse and medical monitoring. Future guidelines should give priority to a tailored approach to TSH suppression therapy in DTC patients.

KEYWORDS:

Adverse effects; Cancer thyroïdien; Effets secondaires; Frénateur; Levothyroxine; Suppressive; TSH; Therapy; Thyroid cancer; Traitement

PMID:
26826483
DOI:
10.1016/S0003-4266(16)30014-2
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center